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Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and among the deadliest 
forms of all cancer types with a five-year survival rate of less than 5%. While currently uncommon in 
the United States, its incidence is rapidly increasing because of hepatitis C and alcohol- and obesity-
related liver disease. In other parts of the world, including Sub-Saharan Africa and Southeast Asia 
where hepatitis infections are highly prevalent, HCC is one of the most prevalent cancers. A better 
understanding of the disease progression carries the promise to develop better screening methods 
for HCC or improved treatment strategies. Several studies have highlighted that p53 inactivation and 
inhibition of transforming growth factor-beta (TGF-beta) signaling are among the most common 
molecular disruptions in HCC. As a critical regulator of the cell cycle and apoptosis, p53 is frequently 
targeted for inactivation during liver tumorigenesis, through a variety of mechanisms. TGF-beta is a 
cytokine that controls a variety of processes in healthy cells including proliferation and differentiation. 
However, in several cancers including HCC, studies have shown that the cellular context can direct 
TGF-beta’s function to be either tumor suppressive or oncogenic. In light of this, studying the role of 
TGF-beta in the presence of other gene mutations is relevant to understanding how TGF-beta 
affects HCC. 
To study the role of TGF-beta signaling in the context of p53 inactivation within liver cells, 
postdoctoral fellow Dr. Shelli Morris and corresponding author Dr. William Grady together with 
colleagues in the Clinical Research Division have generated a new mouse model system to study 
how inactivation of p53 and TGF-beta signaling cooperate in vivo during HCC development. Drs. 
Morris and Grady used a conditional deletion mouse model to eliminate expression of Tp53 and the 
TGF-beta receptor, type II (Tgfbr2) specifically in liver cells. While inactivation of Tgfbr2 alone did not 
induce liver tumors, deletion of Tp53 resulted in liver tumors in approximately 40% of mice within 
one year. However, coordinated loss of both Tp53 and Tgfbr2 reduced the frequency of tumors to 
17% of mice, delayed tumor development, and impaired metastasis. Thus loss of p53 in the setting 
of intact TGF-beta signaling results in earlier tumor development, metastasis and lower survival 
rates relative to mice lacking both Tp53 and Tgfbr2. To understand how TGF-beta promotes 
tumorigenesis in the setting of p53 inactivation, the authors examined how TGF-beta affected  
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downstream signaling and gene expression. Liver tumors from p53-deficient mice show increased 
levels of the clinical biomarker for HCC, alpha-fetoprotein, as well as greater TGF-beta 1 levels (the 
ligand for the TGF-beta receptor), relative to tumors from mice deficient in both Tp53 and Tgfbr2. 
TGF-beta dependent and independent signaling pathways that contribute to gene expression, cell 
activation and growth are also more highly activated in mice lacking only p53. Together these data 
demonstrate that TGF-beta signaling and its downstream effects promote the formation of liver 
tumors and metastasis in the setting of p53 inactivation. 
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H&E stained section of a liver tumor from a mouse deficient for p53 
and TGF-beta receptor (100x magnification). 
 
 
